Charted Launches UK Presence to Deliver ERP-Native AP Automation Across EMEA
6.1.2026 15:00:00 CET | Business Wire | Press Release
Charted, a leading accounts payable automation software and ERP services provider, today announced the official launch of its UK office, to support users in the UK and EMEA. This follows the launch of International Payments and an official rebrand in 2025, continuing the forward path of growth and expansion to assist accounts payable (AP) teams in streamlining their processes with advanced automation and deep AI capabilities.
Charted began a decade ago as a consulting firm implementing ERPs for some of the world’s most complex organizations. After years of solving recurring accounts payable challenges for customers, Charted evolved that expertise into an ERP-native SaaS platform that streamlines end-to-end AP processes for multi-entity, multi-currency businesses.
“Even with modern ERP systems in place, accounts payable remains one of the most manual and fragmented areas of finance, especially for organizations operating across regions, entities and currencies,” said Bernardo Enciso, CEO of Charted. “Charted focuses on solving those gaps directly inside the ERP, helping finance teams reduce friction, improve controls and gain real-time clarity without relying on external systems. We’re excited to bring that approach to customers and partners across the UK and EMEA.”
With a strong presence across North America and international customers in the United Kingdom, Ireland, Germany, the Netherlands and Belgium, the launch of an official expansion to the UK signals a deepening commitment to supporting the region and its partners with dedicated resources and investment in additional internationally-focused products.
“The expansive partner ecosystem in EMEA is an exciting opportunity for Charted,” said Derrick Angle, Head of Global Partnerships at Charted. “We have already had strong interest from local partners and are working to bring our unique approach to end-to-end AP Automation to the region, with plans for future products to address specific paint points. I’m thrilled to have Dominic Reid lead our GTM efforts from our EMEA HQ in London, and we are also welcoming Enes Sarioglu to the team in January to provide local technical support to our customers and partners. It’s imperative to us to maintain our customer-centric approach as we expand, and we couldn’t be happier with the reaction we’ve already received.”
The Charted approach to AP automation focuses on an end-to-end workflow, designed to make the experience frictionless by eliminating integrations and connectors. Working natively within a customer’s ERP suite, the Charted AP process moves from invoicing, vendor onboarding, approvals, payments, document matching and management, to an efficient closing of the books with intelligent accruals, all without having to learn a third-party platform, and keeping audit trails in one place.
Frequently asked questions about expanding into EMEA:
Where is the Charted UK office?
Charted has hired its first two UK-based employees with plans for further additions to support our UK and Europe-based customers. Technical support will be available in local time zones.
Does Charted have UK customers?
Charted currently supports organizations across the United Kingdom, Ireland, Germany, the Netherlands and Belgium in various industries including biotech and pharmaceuticals, financial services, and tech.
Will Charted products be the same in Europe as they are in the US?
Charted products are already used by organizations in a number of European countries, providing complete end-to-end AP Automation. Organizations can expect to use the full suite of invoice automation, with further solutions coming in 2026 to address European needs.
Does Charted offer e-invoicing?
In preparation for our expansion into the UK and Europe, Charted is working to integrate e-invoicing into our accounts payable solution and expect this to go live in Q1 2026. Charted will publish an announcement when e-invoicing has officially launched as part of the Charted AP Automation solution.
Will Charted be set up to comply with established European regulations like GDPR?
Charted is SOC 2 Type 2 compliant and utilizes data protection processes in accordance with European Data Protection Laws, as established by the European Commission or the UK Information Commissioner’s Office, as applicable, under the European Data Protection Laws. You can read more about it under our Privacy Policy.
About Charted
Charted clears the path for finance teams with AP Automation solutions built directly into your ERP—no integrations, no extra systems. Gain real-time clarity on every invoice, approval, and payment so you can focus on what really matters. Eliminate manual data entry with AI-powered capabilities and expense accrual automation to accelerate your month-end close. Combine the power of your full ERP dataset with Charted built-in controls to manage the most complex approvals and workflows, producing results at scale. Backed by decades of ERP best practices and expertise, we enable multi-entity, multi-currency workflows to support your AP automation needs anywhere in the world.
Charted was born from years of hands-on implementation and consulting experience. With consulting roots and product strength, Charted is your one-stop-shop for everything ERP. To find out more, please visit www.charted.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260106606056/en/
Contacts
Media
Alicia Sgromo
Corporate Communications
alicia.sgromo@charted.com
UK
Dominic Reid
Senior Director, Sales & Alliances, EMEA
dominic.reid@charted.com
44 333 057 0942
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom